Boehringer Ingelheim Empowers 380 Regional Experts with Latest Insights in Cardio-Renal-Metabolic Care
Boehringer Ingelheim hosted the ‘CRM 360 standalone meeting’, ‘IMETA CRM Discussions for EXperts (MEDEX)’, to discuss the latest advances in the management of cardio-renal-metabolic conditions
Boehringer Ingelheim unites dermatologists to discuss the management of Generalized Pustular Psoriasis (GPP)
The ‘GPP Summit, discussed latest research and advances in the management of GPP to help improve patient outcomes across Saudi Arabia, and the United Arab Emirates.
Landmark EMPA-KIDNEY trial showed significant benefit of empagliflozin in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
EMPA-KIDNEY Phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting
Boehringer Ingelheim’s ‘CRM 360 Meeting’ Brings Together 300 Medical Experts, Highlighting the Importance of an Integrated Approach to Treat Type 2 Diabetes
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint